There are currently 111 ongoing clinical trials involving Ewing Sarcoma
Of the 111 trials,47 trials are in Phase II
Furthermore, 29 trials are in Phase I
The global pharmaceutical industry is steadily developing new drugs for Ewing Sarcoma, an oncology condition. The largest number of ongoing clinical trials for Ewing Sarcoma is conducted in North America. Europe and Asia-Pacific are among some of the other prominent regions engaged in Ewing Sarcoma-related drug trials.
National Cancer Institute US: The leading ongoing Ewing Sarcoma related clinical trial sponsor
National Cancer Institute US is the top sponsor for Ewing Sarcoma-related ongoing clinical trials.
Children's Oncology Group, Dana-Farber/Harvard Cancer Center, Italian Sarcoma Group, Dana-Farber Cancer Institute Inc, and Sun Yat-sen University are among other notable clinical trial sponsors involved in Ewing Sarcoma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Ewing Sarcoma
Temozolomide (Temodar, Temodal, Astromide) and Carboplatin (Paraplatin, Carboplat, Paraplatine), are key marketed drugs involving Ewing Sarcoma.
Temozolomide (Temodar, Temodal, Astromide) is an alkylating agent that acts as an antineoplastic agent. It functions via the DNA Synthesis inhibitor’s mechanism of action. It is formulated as hard gelatin capsules for the oral route of administration and lyophilized powder for solution for intravenous route of administration. Temozolomide is indicated for the treatment of glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment. Temozolomide was first approved in 1998 and is marketed globally including the US, the UK, Australia, Germany, China, and Japan by Merck Sharp & Dohme Corp.
Carboplatin (Paraplatin, Carboplat, Paraplatine), is an antineoplastic agent and chemotherapeutic agent. It functions via DNA Synthesis Inhibitor mechanism of action. It is formulated as an injection for intravenous use. Carboplatin is indicated for palliative treatment (to ease symptoms rather than provide a cure) in patients with initial/recurred ovarian cancer, small cell lung cancer, head, and neck squamous cell carcinoma. in combination with other drugs. Carboplatin was first approved in 1986 and is marketed globally including the US, France, Germany, China, and Japan by Corden Pharma Switzerland LLC.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer